RARRES2 and metabolic dysfunction-associated steatotic liver disease: Additionally, in obese patients with suspected nonalcoholic fatty liver disease (NAFLD) after L-carnitine supplementation, a significant reduction in the level of chemerin was observed, as well as a decrease in BMI, waist circumference, hip circumference and waist/hip ratio, liver enzymes, fasting plasma glucose and insulin [33].